CD24 and COVID-19: More recently, a non-randomized study by Shapira et al. suggested that Exo-CD24, which includes CD24-containing exosomes, appeared to reduce inflammatory markers and cytokines/chemokines while expediting the recovery of hospitalized COVID-19 patients (106).